Develops immunology and oncology antibody therapies, in-licensed from China and developed globally.
Develops immunology and oncology antibody therapies, in-licensed from China and developed globally.
Has no approved product and is funded by investors rather than sales. It keeps costs down by in-licensing drugs partly developed elsewhere, so it pays milestones and royalties to the originators. Obexelimab, licensed from Xencor, is its lead, aimed at IgG4-related disease, a rare condition that causes organ swelling.
Moat: narrow (IP / patents, regulatory licence). Global development rights to in-licensed China-origin biologics, differentiated but unproven commercially.
Headquarters: Waltham, Massachusetts, US · Founded: 2021 · Employees: 167
Size Zenas BioPharma (ZBIO) is a United States Health Care company (Biotechnology) with a market value of $1.79B, the 1847th largest of 3,085 United States companies the cockpit tracks. Shares closed at $26.42 on 18 Nov 2026.
Performance Over six months the shares gained 35.1%, against -4.6% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue fell 26.7% over the last twelve months (peer median +16.6%); the operating margin is -2,747.6% (peer median -0.2%).
Valuation It trades at 146.1× enterprise value to sales against a peer median of 10.9× (2nd most expensive of 15).
Credit Zenas BioPharma has 1 bond outstanding ($230M).
Short interest Short interest is 16.7% of the free float (30 Oct 2026).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $11.0M | $10.0M | $5.00M | $50.0M | $0 |
| Revenue growth | — | +100% | -90% | — | — |
| Gross profit | $11.0M | $9.94M | $4.86M | $49.9M | -$78,000 |
| EBITDA | -$302M | -$211M | -$164M | -$27.0M | -$75.1M |
| Net income | -$542M | -$378M | -$157M | -$37.1M | -$119M |
| Free cash flow | -$243M | -$172M | -$120M | -$30.5M | -$65.8M |
| Capital expenditure | $3,000 | $18,000 | $131,000 | $17,000 | $2.20M |
| Total debt | $400M | $80.0M | $1.00M | $21.1M | $1.53M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Zenas BioPharma ZBIO | $1.79B | +35% | -27% | -2,748% | 146.1× | n/a |
| Roche RO.SW | $381B | +21% | -1% | 31% | 5.7× | 1.7% |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
| argenx SE Sponsored ADR ARGX | $59.1B | +17% | +71% | 29% | 10.3× | 11.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ZBIO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.2% | -1.6% | 10th lowest of 20 |
| 6-month return | +35.1% | -4.6% | 8th highest of 20 |
| Distance from 52-week high | -40.8% | -33.4% | 6th lowest of 21 |
| Revenue growth (TTM) | -26.7% | +16.6% | 5th lowest of 16 |
| Operating margin | -2,747.6% | -0.2% | 2nd lowest of 16 |
| EV / Sales | 146.1× | 10.9× | 2nd most expensive of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | 146.1× | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 11.7× | 33.0% | +24.8% |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | 18.8× | n/a | n/a |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | 50.6× | n/a | n/a |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | 149.9× | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 4.9× | 22.7% | +3.4% |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | 14.7× | n/a | n/a |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 3.6× | -12.1% | +15.0% |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 4.2× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 1.7× | -7.6% | +33.5% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 6.4× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 14.4× | 33.2% | +16.8% |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
Zenas BioPharma has 1 bond outstanding with $230M face value.